Prime Medicine (PRME) Non-Current Assets (2021 - 2026)

Prime Medicine (PRME) has 6 years of Non-Current Assets data on file, last reported at $156.8 million in Q1 2026.

• Quarterly Non-Current Assets fell 4.6% year-over-year to $156.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $629.6 million (up 47.92% YoY) and the FY2025 annual result came in at $161.4 million, up 88.55% from the prior year.
• Non-Current Assets fell to $156.8 million in Q1 2026, from $161.4 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $164.4 million in Q1 2025 to a low of $50.9 million in Q4 2023.
• A 5-year average of $100.7 million and a median of $86.7 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets soared 103.65% — and 2023, when it fell 20.13%.
• Tracing PRME's Non-Current Assets over 5 years: stood at $63.7 million in 2022, then declined by 20.13% to $50.9 million in 2023, then jumped by 68.3% to $85.6 million in 2024, then soared by 88.55% to $161.4 million in 2025, then retreated by 2.85% to $156.8 million in 2026.
• The last three Non-Current Assets figures came in at $156.8 million (Q1 2026), $161.4 million (Q4 2025), and $153.6 million (Q3 2025), per Business Quant data.